Amneal intros generic Tamiflu for oral suspension
Amneal Pharmaceuticals has introduced its generic Tamiflu for oral suspension (oseltamivir phosphate, 6 mg/ml). The Bridgewater, N.J.-based company’s product is a powder finished dosage that is packaged in bottles with 60 ml of usable volume following constitution.
Amneal’s generic Tamiflu for oral suspension joins generic Tamiflu capsules that it launched in July 2017.
“Approval and launch of this liquid form should be of great assistance to patients and caregivers,” Amneal executive vice president of commercial operations Andy Boyer said. “With a severe flu season upon us, our product should be able to help provide relief to thousands of patients. We are pleased to provide this liquid dosage form to patients, particularly the elderly and young who are unable to use an oral solid form.”
The drug is indicated to prevent the flu and as a treatment in patients who have been symptomatic for less than 48 hours. The drug’s market size was roughly $956 million for the 12 months ended December 2017, according to IQVIA data.
NACDS backs e-prescribing Senate bill
The National Association of Chain Drug Stores is backing legislation introduced in the Senate that would require electronic prescribing of controlled substances for Medicare Part D beneficiaries. The Every Prescription Conveyed Securely Act was introduced Tuesday by Sens. Michael Bennet, D-Colo., and Dean Heller, R-Nev., with Sens. Elizabeth Warren, D-Mass., and Pat Toomey, R-Pa., as co-sponsors.
“NACDS appreciates the leadership of Senators Bennet, Helller, Warren and Toomey in this important work to help confront the opioid-abuse epidemic,” NACDS President and CEO Steve Anderson said. “Electronic prescribing enhances security and curbs waste, fraud and abuse. This legislation is a vital aspect of a more comprehensive and effective approach to protecting families and communities.”
NACDS was one of ten associations and companies to send the senators a letter showing their support for the legislation. In the letter, the Arlington, Va.-based trade organization outlines the advantages of e-prescribing controlled substances, including the ease with which these prescriptions can be tracked and their resistance to forgery. E-prescribing of controlled substances has been a policy goal of NACDS’ and was included in its October letter that outlined its various policy stances to the President’s Commission on Combating Drug Addiction and the Opioid Crisis. NACDS said that its advocated policies are based on based on pharmacists’ experience on the front lines of healthcare, and are based on pharmacy’s longstanding collaboration with law enforcement and health professionals on the complex issue of opioid-abuse prevention.
In January, a Morning Consult poll commissioned by NACDS found that 76% of voters support a requirement to handle all prescriptions electronically as a way to combat the opioid epidemic.
Dr. Reddy’s intros generic Xenazine
Dr. Reddy’s recently launched its generic Xenazine (tetrabenazine tablets). The product is indicated to treat chorea, or involuntary movements, of Huntington’s Disease.
Dr. Reddy’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $322 million for the 12 months ended November 2017, according to IQVIA data.
The drug contains a boxed warning about its potential to increase the risk of depression and suicidality in patients.